ALLMedicine™ Chondrosarcoma Center

May 15th, 2022 - Loss-of-function mutations in EED and SUZ12, core components of the polycomb repressive complex 2 (PRC2), occur in >90% of sporadic and radiation-associated malignant peripheral nerve sheath tumors (MPNST) and in roughly 70% of NF1-related tumors....

May 14th, 2022 - To evaluate the experience and effects of resection and reconstruction of 4 cases of huge tumors in the chest wall. The clinical data of 4 patients with huge tumors in the chest wall from July 2015 to January 2020 were collected and analyzed. Ther...

May 6th, 2022 - This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

May 5th, 2022 - Chordomas are malignant tumors that develop along the neuraxis between skull-base and sacrum. Chondrosarcomas show similarities with chordomas, yet show less malignant behavior. LIM and SH3 protein 1 (LASP1) is a cytoskeletal protein known to prom...

May 3rd, 2022 - Practice Essentials A chordoma is a low-grade, slow-growing, but locally invasive and locally aggressive tumor. Chordomas belong to the sarcoma family of tumors. They arise from remnants of the notochord and occur in the midline along the spinal a...

May 6th, 2022 - This study is being done to see whether AG-120 is an effective and safe treatment for people with advanced/metastatic or recurrent chondrosarcoma that has IDH1 mutation.

Apr 28th, 2022 - This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, ...

Apr 20th, 2022 - Chondrosarcoma and liposarcoma consists of different subtypes with a wide range of patient survival. Current treatment options consist of wide surgical resection, however for patients with a local recurrence or metastatic disease the outcome is po...

Apr 4th, 2022 - METHODOLOGY: Randomized, placebo-controlled, multicentric, phase II study -This is a double-blind placebo-controlled trial, with 5 cohorts: cohort A: Osteosarcoma, cohort B: Ewing sarcoma, cohort C: Chondrosarcoma, cohort D : chondroma, cohort E: ...

Jan 14th, 2022 - We intend to explore the response of chondrosarcoma to PD-1 monoclonal antibody and the influence of different IDH genotypes on PD-1 monoclonal antibody response. Patients with unresectable locally advanced or metastatic chondrosarcomas(CS), inclu...

Oct 6th, 2021 - Jonathan C. Trent, MD, PhD Soft tissue sarcoma treatments have significantly advanced within the past year with new available agents, others in the pipeline, and the continued search for biomarkers to make treatment more personalized for patients...

Oct 6th, 2021 - Sarcoma of mobile vertebral column continues to be a rare finding in patients, but is one with poor survival outcomes and varying prognostic factors, explained R. Lor Randall, MD. Because primary sarcomas that originate in the spine are so rare, ...

Oct 6th, 2021 - Tissue-engineered platforms could pave the way for a deeper understanding of cancer arising in or metastasizing to the bone and ultimately lead to targeted therapeutic developments, according to a review published in the Journal of Biomechanics. ...

Oct 6th, 2021 - Bob T. Li, MD, MPH Fam-trastuzumab deruxtecan-nxki (Enhertu; DS-8201), a HER2-directed antibody¬—drug conjugate (ADC), demonstrated significant clinical activity in multiple non-breast, non-gastric cancer solid tumor types, according to findings ...

Apr 2nd, 2021 - Transcript:William D. Tap, MD: One of the things I want to get back to is this comment that sarcoma is a chemotherapy-insensitive disease. I’m sure we can talk about, and we will, some diseases that are chemotherapy-insensitive. But what’s your th...